| __timestamp | MannKind Corporation | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 100244000 | 55430000 |
| Thursday, January 1, 2015 | 29674000 | 65510000 |
| Friday, January 1, 2016 | 14917000 | 71160000 |
| Sunday, January 1, 2017 | 14118000 | 70644000 |
| Monday, January 1, 2018 | 8737000 | 70418000 |
| Tuesday, January 1, 2019 | 6900000 | 63238000 |
| Wednesday, January 1, 2020 | 6248000 | 59777000 |
| Friday, January 1, 2021 | 12312000 | 60152000 |
| Saturday, January 1, 2022 | 19721000 | 54540000 |
| Sunday, January 1, 2023 | 31283000 | 52243000 |
| Monday, January 1, 2024 | 64536000 |
Unleashing the power of data
In the competitive world of pharmaceuticals, research and development (R&D) is the lifeblood of innovation. MannKind Corporation and Taro Pharmaceutical Industries Ltd. have taken distinct paths in their R&D investments over the past decade. From 2014 to 2023, MannKind's R&D spending saw a dramatic decline of nearly 70%, from its peak in 2014 to its lowest in 2020. However, a resurgence is evident with a 400% increase by 2023. In contrast, Taro Pharmaceutical maintained a steady R&D investment, averaging around $63 million annually, with minor fluctuations. This consistent approach underscores Taro's commitment to sustained innovation. The data for 2024 is incomplete, highlighting the dynamic nature of financial reporting. As these companies navigate the future, their R&D strategies will be pivotal in shaping their competitive edge and market leadership.
R&D Insights: How Novartis AG and MannKind Corporation Allocate Funds
Research and Development: Comparing Key Metrics for Pfizer Inc. and MannKind Corporation
Teva Pharmaceutical Industries Limited vs MannKind Corporation: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: Incyte Corporation vs Taro Pharmaceutical Industries Ltd.
Comparing Innovation Spending: Summit Therapeutics Inc. and MannKind Corporation
Who Prioritizes Innovation? R&D Spending Compared for Sarepta Therapeutics, Inc. and MannKind Corporation
R&D Spending Showdown: Exelixis, Inc. vs Taro Pharmaceutical Industries Ltd.
Research and Development Expenses Breakdown: Pharming Group N.V. vs Taro Pharmaceutical Industries Ltd.
Research and Development Investment: Grifols, S.A. vs Taro Pharmaceutical Industries Ltd.
R&D Insights: How Verona Pharma plc and MannKind Corporation Allocate Funds
R&D Spending Showdown: Perrigo Company plc vs MannKind Corporation
Research and Development Investment: Vericel Corporation vs MannKind Corporation